Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Cancer Vaccines and Combination Immunotherapies
share announcement

Cancer Vaccines and Combination Immunotherapies

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 4411

Special Issue Editors

Dr. Jessica Chacon

E-Mail Website
Guest Editor
Health Sciences Center, Texas Tech University, Lubbock, TX 79409, USA
Interests: cancer
Dr. Richard Wu

E-Mail Website
Guest Editor
Wexner Medical Center, Ohio State University, Columbus, OH 43210, USA
Interests: TIL therapy; immune checkpoint blockade; melanoma

Special Issue Information

Dear Colleagues,

Over the last decade, immense progress has been made within the field of cancer immunotherapy. Although immunotherapy has rapidly become a primary mode of cancer treatment, the field has proved challenging due to the ability of tumor cells to manipulate the tumor microenvironment and actively evade detection and elimination by the host immune system. Great interest has been seen in the development, identification, and production of treatments aimed at eliciting a strong immune response against antigens expressed by the tumor cells, mutation-derived antigens, and the tumor microenvironment.

The future of cancer treatment lies in the development of therapies that effectively produce an immune response by targeting the tumor microenvironment. Cancer therapeutic vaccines, either alone or as part of combination immunotherapy, are actively being researched as a way to accomplish this.

This Special Issue, titled “Cancer Immunotherapy: Vaccines and Combination Immunotherapies” will focus on fundamental research on cancer vaccines and combination immunotherapies. Special attention will be given to the topic of targeted cancer vaccines and combination immunotherapies aimed at modifying the tumor microenvironment, as well as the challenges associated with the development of these novel therapeutic approaches. We invite you to share original research articles as well as up to date reviews.       

Research areas may include (but are not limited to) the following: neoantigen vaccines, cancer therapeutic vaccines, combination immunotherapy, DNA vaccines, dendritic cell-based vaccines, cell-based vaccines, nucleic-acid-based vaccines, neoadjuvant therapy, immune checkpoint therapy, nanoparticle immune therapy, anti-CTLA-4 therapy, anti-PDX therapy, and adoptive cell therapy.

We look forward to receiving your contributions.

Dr. Jessica Chacon
Dr. Richard Wu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine
  • cancer immunotherapy
  • immune checkpoint therapy
  • immunoediting
  • nanoparticle therapy
  • neoadjuvant therapy
  • adoptive cell therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

22 pages, 1026 KiB  
Review
Sending a Message: Use of mRNA Vaccines to Target the Tumor Immune Microenvironment
by Fabiola Ramirez, Angelica Zambrano, Robert Hennis, Nathan Holland, Rajkumar Lakshmanaswamy and Jessica Chacon
Vaccines 2023, 11(9), 1465; https://doi.org/10.3390/vaccines11091465 - 07 Sep 2023
Cited by 3 | Viewed by 1722
Abstract
While cancer immunotherapies have become central to treatment, challenges associated with the ability of tumors to evade the immune system remain significant obstacles. At the heart of this issue is the tumor immune microenvironment, the complex interplay of the tumor microenvironment and the [...] Read more.
While cancer immunotherapies have become central to treatment, challenges associated with the ability of tumors to evade the immune system remain significant obstacles. At the heart of this issue is the tumor immune microenvironment, the complex interplay of the tumor microenvironment and the immune response. Recent advances in mRNA cancer vaccines represent major progress towards overcoming some of the challenges posed by deleterious components of the tumor immune microenvironment. Indeed, major breakthroughs in mRNA vaccine technology, such as the use of replacement nucleotides and lipid nanoparticle delivery, led to the vital success of mRNA vaccine technology in fighting COVID-19. This has in turn generated massive additional interest and investment in the platform. In this review, we detail recent research in the nature of the tumor immune microenvironment and in mRNA cancer vaccines and discuss applications by which mRNA cancer vaccines, often in combination with various adjuvants, represent major areas of potential in overcoming tumor immune microenvironment-imposed obstacles. To this end, we also review current mRNA cancer vaccine clinical trials. Full article
(This article belongs to the Special Issue Cancer Vaccines and Combination Immunotherapies)
►▼ Show Figures

Figure 1

16 pages, 1032 KiB  
Review
Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma
by Fenge Li, Huancheng Wu, Xueming Du, Yimo Sun, Barbara Nassif Rausseo, Amjad Talukder, Arjun Katailiha, Lama Elzohary, Yupeng Wang, Zhiyu Wang and Gregory Lizée
Vaccines 2023, 11(9), 1460; https://doi.org/10.3390/vaccines11091460 - 05 Sep 2023
Cited by 2 | Viewed by 2343
Abstract
The epidermal growth factor receptor (EGFR) plays crucial roles in several important biological functions such as embryogenesis, epithelial tissue development, and cellular regeneration. However, in multiple solid tumor types overexpression and/or activating mutations of the EGFR gene frequently occur, thus hijacking the EGFR [...] Read more.
The epidermal growth factor receptor (EGFR) plays crucial roles in several important biological functions such as embryogenesis, epithelial tissue development, and cellular regeneration. However, in multiple solid tumor types overexpression and/or activating mutations of the EGFR gene frequently occur, thus hijacking the EGFR signaling pathway to promote tumorigenesis. Non-small cell lung cancer (NSCLC) tumors in particular often contain prevalent and shared EGFR mutations that provide an ideal source for public neoantigens (NeoAg). Studies in both humans and animal models have confirmed the immunogenicity of some of these NeoAg peptides, suggesting that they may constitute viable targets for cancer immunotherapies. Peptide vaccines targeting mutated EGFR have been tested in multiple clinical trials, demonstrating an excellent safety profile and encouraging clinical efficacy. For example, the CDX-110 (rindopepimut) NeoAg peptide vaccine derived from the EGFRvIII deletion mutant in combination with temozolomide and radiotherapy has shown efficacy in treating EGFRvIII-harboring glioblastoma multiforme (GBM) patients undergone surgery in multiple Phase I and II clinical trials. Furthermore, pilot clinical trials that have administered personalized NeoAg peptides for treating advanced-stage NSCLC patients have shown this approach to be a feasible and safe method to increase antitumor immune responses. Amongst the vaccine peptides administered, EGFR mutation-targeting NeoAgs induced the strongest T cell-mediated immune responses in patients and were also associated with objective clinical responses, implying a promising future for NeoAg peptide vaccines for treating NSCLC patients with selected EGFR mutations. The efficacy of NeoAg-targeting peptide vaccines may be further improved by combining with other modalities such as tyrosine kinase or immune checkpoint inhibitor (ICI) therapy, which are currently being tested in animal models and clinical trials. Herein, we review the most current basic and clinical research progress on EGFR-targeted peptide vaccination for the treatment of NSCLC and other solid tumor types. Full article
(This article belongs to the Special Issue Cancer Vaccines and Combination Immunotherapies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop